NCT07487389Available不适用
Zilganersen Expanded Access Program for Individuals With Alexander Disease
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
The purpose of the expanded access program (EAP) is to provide access to zilganersen for eligible individuals with Alexander disease (AxD).
详细描述
This is an expanded access program (EAP) for eligible individuals diagnosed with Alexander disease residing in the United States, prior to approval of zilganersen by the local regulatory agency (FDA).
A medical doctor must decide whether the potential benefits of zilganersen outweigh the potential risks based on the individual patient's medical history and program eligibility criteria.
Access can be requested via the contact information below.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Years 至 99 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Approved drug or drugs available for treatment did not work for the patient, or the patient cannot tolerate the side effects of the FDA-approved drug or drugs for treatment of AxD.
- •Patients who are ≥ 2 years old.
- •Patients who have a clinical phenotype and brain imaging consistent with a diagnosis of AxD.
- •Patients who have a documented variant in the GFAP gene.
- •Patient resides in and is a resident of the US.
排除标准
- •Patients who have any medical history, physical exam findings, or clinically significant laboratory abnormalities that contraindicate performing an LP for ITB administration of zilganersen.
- •Patients who have current obstructive hydrocephalus.
- •Patients who have the presence of a functional ventriculoperitoneal shunt for the drainage of CSF.
- •Patients who have any other medical history or current conditions, which, in their Treating Physician's opinion, would make the patient unsuitable for inclusion (e.g., active Hepatitis B virus or hepatitis C virus infection, severe hepatic or renal disease, uncontrolled acute or chronic condition, etc.).
- •Patients who are pregnant or plan to become pregnant, or patients who are breastfeeding.
- •Other inclusion/exclusion criteria may apply.
研究者
相似试验
No Longer Available
不适用
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)NCT04278235AbbVie
No Longer Available
不适用
Expanded Access for AG-221Acute Myeloid LeukemiaNCT03723057Celgene
No Longer Available
不适用
Expanded Access to FosigotifatorVanishing White MatterCree LeukoencephalopathyNCT06594016AbbVie
已完成
不适用
Expanded Access Program to provide Nusinersen to Patients with infantile-onset spinal muscular atrophy (SMA)G12.0Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]DRKS00011547Klinik für Neuropädiatrie und MuskelerkrankungenZentrum für Kinder- und JugendmedizinUniversitätsklinikum Freiburg61
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.